Bioequivalence of Levothyroxine Preparations Issu

Authors: Betty J Dong John G Gambertoglio Francis S Greenspan Walter W Hauck

Publish Date: 1997/09/17

Volume: 278, Issue: 11, Pages: 898-898

PDF Link

Abstract

In Reply  —We would like to acknowledge the many letters and encouraging words of support that we have received from both old and new colleagues since the publication of our study We do not believe that our story suggests that all future collaborations with industry are doomed We agree with Dr Dreyer and others12 that academic researchers should not agree to restrictive contracts forbidding publication rightsDr DeGroot and Drs St Germain and Ridgway disagree with our findings DeGroots understanding that AUC data are only logical for compounds with rapid turnover is incorrect and a revisiting of pharmacokinetic principles is needed The AUC measurements are valid for thyroxine with a halflife of 7 days if it is taken under steady and comparable conditions as in our study The pharmacokinetic data and the clinical outcome of the subjects who received each product for 6 weeks clearly show that the 4 levothyroxine preparations

Keywords: